Diagnosis. Anti-TNF-agent induced psoriasiform skin rash. Management. Discontinuation of anti-TNF therapy. The patient opted to have his gastrointestinal symptoms treated with oral mesalazine and ...

TRIKAFTA can cause serious and potentially fatal drug-induced liver injury. Cases of liver failure leading to transplantation and death have been reported in patients with and without a history of ...

But, the approval came with an upgraded safety warning. Trikafta now carries a boxed warning for potential drug-induced liver injury and liver failure. Alyftrek was also given a boxed warning for ...

Vertex Pharmaceuticals (VRTX) announced the U.S. Food and Drug Administration has approved the expanded use of Trikafta for the treatment of people with cystic fibrosis ages 2 and older who have ...

This confirmed the diagnosis of an anti-TNF-agent-induced psoriasiform skin rash. The skin manifestations caused the patient sufficient distress to prevent further use of a TNF antagonist.

Given that these rashes are typically diagnosed based on clinical features without histological information, we suggest the use of the general term 'anti-TNF-induced psoriasiform rashes' until the ...